Does lipoprotein(a) increase atherosclerotic cardiovascular risk independently of LDL cholesterol?

Clinical and epidemiological evidence

• Independent ASCVD Risk: Extensive epidemiological and genetic data, including large-scale Mendelian randomization studies and prospective cohort analyses (such as those from the UK Biobank involving hundreds of thousands of participants), demonstrate a linear, causal relationship between lipoprotein(a) [Lp(a)] concentration and atherosclerotic cardiovascular disease (ASCVD).
• Independence from LDL-C: Factorial and multivariable Mendelian randomization analyses establish that this risk is independent of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B-100 (apoB-100) levels. Elevated Lp(a) contributes to residual cardiovascular risk even in patients who achieve very low LDL-C targets (<55 mg/dL) under high-intensity lipid-lowering therapy.

Pathogenic and molecular mechanisms

• Apoprotein Structure: Lp(a) consists of an LDL-like particle containing a single molecule of apoB-100 covalently linked via a disulfide bond to a highly polymorphic glycoprotein, apolipoprotein(a) [apo(a)].
• Atherothrombotic Potential: Due to its structural homology with plasminogen, the apo(a) moiety competes with plasminogen for binding sites on fibrin and endothelial cells, thereby inhibiting tissue plasminogen activator (tPA)-mediated fibrinolysis and promoting a pro-thrombotic state.
• Pro-inflammatory Cargo: Lp(a) serves as the primary plasma carrier of highly reactive oxidized phospholipids (OxPL). These OxPLs are bound to the kringle domains of apo(a), driving endothelial cell activation, monocyte recruitment, and foam cell formation, which accelerates the progression of calcific aortic valve stenosis and arterial wall inflammation.

Bottom line

• Lipoprotein(a) is an apoB-100–containing lipoprotein that causally and independently increases the risk of atherosclerotic cardiovascular disease and aortic stenosis through unique pro-inflammatory and pro-thrombotic pathways—specifically mediated by apo(a) and oxidized phospholipids—which are entirely distinct from the lipid accumulation pathways associated with LDL-C alone.